REFERENCES

  1. World Health Organization (WHO). Global hepatitis report, 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. Available at: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (cited 22 March 2020).

  2. McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modeling progress toward elimination of hepatitis B in Australia. Hepatology 2020;71:1170-81. 1% cited in: MacLachlan J, Allard N, Carville K, Haynes K, Cowie B. Mapping progress in chronic hepatitis B: geographic variation in prevalence, diagnosis, monitoring and treatment, 2013–15. Aust N Z J Public Health 2018;42:62‐8. Which was cited in:  MacLachlan JH, et al. The burden of chronic hepatitis B virus infection in Australia, 2011. Aust N Z J Public Health 2013;37(5):416-22. I would use Kirby Institute 2018 (Ref 25)

  3. Australian Government. Australian Institute for Health and Welfare (AIHW). Cancer in Australia 2019. Available at: https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2019/contents/table-of-contents (cited 22 March 2020).

  4. Australian Government Department of Health. Third National Hepatitis B Strategy 2018-2022. 2018. Available at: https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1/$File/Hep-B-Third-Nat-Strategy-2018-22.pdf (cited 22 March 2020).

  5. WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO

  6. Australian Red Cross Blood Service. Ensuring blood safety [internet]. Available at: http://www.donateblood.com.au/about-blood/ensuring-safety (cited 22 March 2020).

  7. Australian Government. Department of Home Affairs. What health examinations you need [internet]. Available at: https://immi.homeaffairs.gov.au/help-support/meeting-our-requirements/health/what-health-examinations-you-need (cited 29 April 2020).

  8. Australian Government. Department of Health. Communicable Diseases Network Australia (CDNA). Australian national guidelines for the management of healthcare workers living with blood borne viruses and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses [internet]. Revised September 2019. . Available at: https://www1.health.gov.au/internet/main/publishing.nsf/content/cda-cdna-bloodborne.htm (cited 29 April 2020).

  9. National Health and Medical Research Council, Australian Research Council, Universities Australia. National statement on ethical conduct in human research 2007 (Updated 2018). Available at: http://www.nhmrc.gov.au/guidelines-publications/e72(cited 22 March 2020).

  10. Otağ F. False positive HBsAg result in blood donors due to administration of three different recombinant DNA Hepatitis B vaccines. Vaccine 2003;21:3734-7.

  11. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Government Department of Health. Australian Immunisation Handbook. Hepatitis B. 2018 [internet]. Available at: https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/hepatitis-b (cited 22 March 2020)

  12. Australian Government. Department of Health. Therapeutic Goods Administration. Overview of the regulatory framework for in-vitro diagnostic medical devices [internet]. Available at: http://www.tga.gov.au/industry/ivd-framework-overview.htm (cited 22 March 2020).

  13. Australian Government. Federal Register of Legislation. Therapeutic Goods Act 1989. Act No. 21 of 1990 [internet]. Available at: http://www.comlaw.gov.au/Series/C2004A03952 (cited 22 March 2020).

  14. National Association of Testing Authorities (NATA). National Association of Testing Authorities, Australia [internet]. Available at: https://www.nata.com.au (cited 22 March 2020).

  15. Australian Government. Department of Health. National Pathology Accreditation Advisory Council (NPAAC) [internet]. Available at: http://www.health.gov.au/npaac (cited 22 March 2020).

  16. Australian Government. Department of Health. Therapeutic Goods Administration. Australian regulatory guidelines for biologicals (ARGB) [internet]. Available at: http://www.tga.gov.au/industry/biologicals-argb.htm (cited 22 March 2020).

  17. Shadur B, MacLachlan J, Cowie B. Hepatitis D virus in Victoria, 2000-2009. Intern Med J 2013;43:1081-7.

  18. Muñoz BE, Pérez CE, Gómez ER, Ortega GI. Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab. Gastroenterol Hepatol 2010;33:377-81.

  19. Arnold DM, Crowther MA, Meyer RM, et al. Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion 2010;50:2577-81.

  20. Parker S, Gil E, Hewitt P, et al. Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin. BMC Infect Dis 2014;14:99.

  21. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS; Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol 2019;71:397-408.

  22. MacLachlan JH, Allard N, Cowie BC. Disparities in hepatitis B vaccine funding in Australian jurisdictions: limiting access for priority populations. Aust NZ J Public Health 2015;39:192. Available at: http://onlinelibrary.wiley.com/doi/10.1111/1753-6405.12316 (cited 22 March 2020).

  23. Centres for Disease Control and Prevention (CDC). CDC Yellow Book 2020. Health Information for International Travel. Chapter 4. Travel-related infectious diseases. Map 4-04. Prevalence of hepatitis B virus infection. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/hepatitis-b (cited 22 March 2020)

  24. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009;27:6550-7.

  25. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Available at: https://kirby.unsw.edu.au/report/hiv-viral-hepatitis-and-sexually-transmissible-infections-australia-annual-surveillance (cited 29 April 2020).

  26. Cowie B, Karapanagiotidis T, Enriquez A, Kelly H. Markers of hepatitis B virus infection and immunity in Victoria, Australia, 1995 to 2005. Aust NZ J Public Health 2010;34:72-8.

  27. He WQ, Duong MC, Gidding H, et al. Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016. J Viral Hepat 2020;27:74-80.

  28. Australian Bureau of Statistics. 2071.0 – Census of Population and Housing. Aboriginal and Torres Strait Islander Population, 2016 [internet]. Available at: https://www.abs.gov.au/ausstats/[email protected]/Lookup/by%20Subject/2071.0~2016~Main%20 Features~Aboriginal%20and%20Torres%20Strait%20islander%20Population%20Article~12 (cited 30 April 2020).

  29. Homewood J, Coory M, Dinh B. Cancer among people living in rural and remote indigenous communities in Queensland: an update 1997–2002. Brisbane: Queensland Government. Queensland Health; Information circular 70, August 2005. Available at: https://www.health.qld.gov.au/__data/assets/pdf_file/0028/144685/info70.pdf (Cited 22 March 2020).

  30. Australian Bureau of Statistics. 2075.0 – Census of Population and Housing: Counts of Aboriginal and Torres Strait Islander Australians, 2016 [internet]. Available at: https://www.abs.gov.au/AUSSTATS/[email protected]/Lookup/2075.0Main%20Features202016?OpenDocument (cited 29 April 2020).

  31. Australian Institute of Health and Welfare. Cancer in Australia 2019. Cancer Series No. 119. Cat. no. CAN 123. Canberra: AIHW; 2019. Available at: https://www.aihw.gov.au/getmedia/8c9fcf52-0055-41a0-96d9-f81b0feb98cf/aihw-can-123.pdf.aspx?inline=true (cited 30 April 2020).

  32. Campbell DH, Sargent JW, Plant AJ. The prevalence of markers of infection with hepatitis B virus in a mixed-race Australian community. Med J Aust 1989;150:489-92.

  33. Dent E, Selvey CE, Bell A, Davis J, McDonald MI. Incomplete protection against hepatitis B among remote Aboriginal adolescents despite full vaccination in infancy. Commun Dis Intell 2010:34;435-9. Available at: http://www.health.gov.au/internet/main/publishing.nsf/content/cda-cdi3404-pdf-cnt.htm/$FILE/cdi3404d.pdf (cited 22 March 2020).

  34. Gilson RJ, de Ruiter A, Waite J, et al. Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage. Sex Transm Infect 1998;74:110-5. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1758098/ (cited 22 March 2020).

  35. Gamagedara N, Weerakoon AP, Zou H,et al. Cross-sectional study of hepatitis B immunity in MSM between 2002 and 2012. Sex Transm Infect 2014;90:41-5. Available at: https://sti.bmj.com/content/90/1/41.long (cited 22 March 2020).

  36. Victoria State Government. Department of Health and Human Services. Hepatitis B infection control in haemodialysis centres. A Victorian Renal Clinical Network consensus document. 2017. Available at : https://www2.health.vic.gov.au/about/publications/policiesandguidelines/hepatitis-b-infection-control-in-haemodialysis-centres# (cited 30 April 2020).

  37. Doyle J, Raggatt M, Slavin M, et al. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Med J Aust 2019;210:462-8.

  38. Australian Government. Department of Health. Australian national notifiable diseases case definitions. Hepatitis B (newly acquired) case definition [internet]. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_hepbnew.htm (cited 22 March 2020).

  39. Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Management of hepatitis B in pregnancy. November 2019. Available at: https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Management-of-Hepatitis-B-in-Pregnancy-(C-Obs-50).pdf?ext=.pdf (cited 22 March 2020).

  40. Australasian Society for HIV Medicine (ASHM). Antenatal testing and blood-borne viruses (BBVs). Updated March 2015. Available at: PBB_ANTENATAL_Testing_2015.pdf (cited 1 May 2020).

  41. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012;19:e18-25.

  42. Wen W-H, Chang M-H, Zhao L-L, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013;59:24-30.

  43. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190:489-92.

  44. Lampertico P, Agarwal K, Berg T, et al. For the European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.

  45. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560-99.

  46. Schillie S, Murphy TV, Fenlon N, Ko S, Ward JW. Update: shortened interval for postvaccination serologic testing of infants born to hepatitis B-infected mothers. MMWR Morb Mortal Wkly Rep 2015;64:1118-20.

  47. Thilakanathan C, Wark G, Maley M, et al. Mother-to-child transmission of hepatitis B: Examining viral cut-offs, maternal HBsAg serology and infant testing. Liver Int 2018;38:1212-9.

  48. National Health and Medical Research Council, Australian Commission on Safety and Quality in Health Care. Australian guidelines for the prevention and control of infection in healthcare. Canberra: National Health and Medical Research Council; 2019.

  49. Centre for Culture, Ethnicity and Health. Cultural competence. Tip sheets on cultural competence based on Indicators of Cultural Competence in Health Care Delivery Organisations: An Organisational Cultural Competence Assessment Profile , prepared by the Lewin Group Inc. under contract with the USA Department of Health and Human Services (2002). 2012 [internet]. Available at: https://www.ceh.org.au/resource-hub/cultural-competence-in-governance/ (cited 22 March 2020).

  50. Fifth National Aboriginal and Torres Strait Islander Blood Borne Viruses and Sexually ransmissible Infections strategy 2018-2022. Available at: https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1//$File/ATSI-Fifth-Nat-Strategy-2018-22.pdf Strategy-2018-22.pdf. Cited 11 October 2020.

  51. Australian Government. Federal Register of Legislation. Therapeutic Goods (Medical Devices) Regulations 2002. Available at: https://www.legislation.gov.au/Details/F2017C00534/Controls/ (cited 1 May 2020).

  52. Australian Government. Department of Health. Therapeutic Goods Administration. Reporting adverse events [internet]. 30 October 2019. Available at: https://www.tga.gov.au/reporting-adverse-events(cited 1 May 2020).

  53. Australian Government. Department of Health. Medicare Benefits Schedule Book. Category 6. 1 December 2018. Publications Number: 12289 [internet] Available at: http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/04AA67013FD6E6C0CA 25834700038565/$File/201812-Cat6.pdf (cited 2 May 2020)

  54. National Health and Medical Research Council, Australian Commission on Safety and Quality in Health Care. Australian guidelines for the prevention and control of infection in healthcare. Canberra: National Health and Medical Research Council; 2019.